Montis Biosciences

Montis Biosciences develops next-generation therapeutics that harness the dual biology of complement C1q by simultaneously targeting the complement and myeloid axes. The company's pipeline targets neuroinflammatory diseases, with a lead program in Guillain-Barré syndrome. Montis is headquartered in Leuven, Belgium, and is supported by investors including DROIA Ventures, Pfizer Ventures, Polaris Innovation Fund, ALSA Ventures and VIB.